MIKROGEN Acquires Lophius Biosciences To Expand Into T Cell-Based Testing Market

In the future, the Lophius-developed in vitro diagnostic kit T-Track^® CMV will be marketed by Mikrogen. By measuring CMV-specific cell-mediated immunity, T-Track^® CMV adds an additional dimension to anti-CMV treatment decision-making in transplantation. T-Track^® CMV complements the currently used CMV viral load tests, empowering clinicians to make personalized treatment decisions. In addition, Mikrogen will pursue Lophius’ development programs, which include (i) a highly sensitive blood-based next-generation infection detection test that allows to rule-out a tuberculosis (TB) infection early in the diagnostic process, and (ii) a breakthrough solution to reliably differentiate between latent and treatment-requiring active TB infections.

“We are looking forward to welcome on board our new colleagues from Lophius. We believe that bringing together the two teams and their complementary expertise will accelerate our innovative strength to develop new diagnostic solutions, in particular in the area of T cell-based tests to measure the pathogen specific immune status, for immune monitoring and personalized risk stratification. We are really excited to start this journey today,” commented Dr. Erwin Soutschek, CEO & Managing Director of Mikrogen GmbH.

About MIKROGEN GmbH

Mikrogen is a global provider of system solutions for medical laboratory diagnostics. The company´s success factors are the combination of excellent genetic engineering know-how with scientific background and consistent customer orientation. Mikrogen offers a wide range of system solutions for the indirect detection (antibodies) and direct detection (PCR) of pathogens. The company’s focus is on the serology of bacterial, fungal, parasitic and viral infections as well as on autoimmune and cancer diseases.

Over 30 Years, since 1989, Mikrogen produces antigens for clinical diagnostics. Mikrogen transcends the boundaries of conventional diagnostics and opens up new possibilities for infectious serology with additional confirmation, enabling concrete statements at the time of infection and the stage of the disease. This may provide substantial therapy and support in disease management. Mikrogen’s extensive product portfolio covers nearly the entire spectrum of clinical images, such as sexually transmitted diseases and prenatal diagnostics, gastrointestinal infections, respiratory infections, emerging and organ infections, tick / insect borne infections and tropical fever. Mikrogen’s automation solutions are comprehensive product lines and can be used modularly within the product lines. The company offers both semi-automatic and fully automatic automation solutions and a very competent service. Mikrogen´s molecular diagnostics for infectious diseases includes both its own highly-qualified and modular product line as well as nucleic acid extraction and a complete MDx workflow, including Extraction, Liquid handling, Amplification and Interpretation.

The highly skilled and experienced employees are the key to the success of Mikrogen. To improve the performance of clinical diagnostics constantly, more than 130 staff members work continuously on the implementation of latest scientific results. Competent consulting and support as well as specialized sales representative make Mikrogen the partner of choice in the diagnostic laboratory.

Contact:

MIKROGEN Diagnostik GmbH
Floriansbogen 2-4
82061 Neuried | Germany
Tel +49 89 54801-0
E-Mail: mikrogen@mikrogen.de
www.mikrogen.de